COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study ; day:18 ; month:4 ; year:2024 ; pages:1-8
Annals of hematology ; (18.4.2024), 1-8
- Creator
-
Thau, Sophie
Poulsen, Christian Bjørn
Brieghel, Christian
Larsen, Morten Kranker
Wiese, Lothar
Nielsen, Xiaohui Chen
Pedersen, Lars Møller
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-024-05738-4
- URN
-
urn:nbn:de:101:1-2406302120145.709737985433
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Thau, Sophie
- Poulsen, Christian Bjørn
- Brieghel, Christian
- Larsen, Morten Kranker
- Wiese, Lothar
- Nielsen, Xiaohui Chen
- Pedersen, Lars Møller
- SpringerLink (Online service)
Other Objects (12)
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States